Catalent to buy clinical trial supply business of Aptuit

Expands Development & Clinical Services business

Catalent Pharma Solutions is to purchase the clinical trial supply business of Aptuit for US$410m (€283m), adding development and clinical manufacturing expertise and capacity. After completing the deal, Greenwich, Connecticut-based Aptuit will focus on its drug discovery and early development services.

The transaction is expected to close by the end of the year.

‘This transaction builds important expertise, scale and capability for our Development & Clinical Services business to meet better our customers’ needs globally,’ said John Chiminski, president and ceo of Catalent.

He added that the deal also strengthens the Somerset, New Jersey based firm’s development solutions and advanced delivery technologies for drugs and biologics.

Aptuit retains development and manufacturing facilities in the US, Europe and Asia, where around 900 people are employed. The firm offers a complete set of integrated early development capabilities including discovery, early development, solid state chemistry, sterile fill parenterals, high potency APIs through Class V and formulation development.

‘This agreement puts Aptuit in a better position to focus on the scientific excellence that our customers want,’ said Timothy Tyson, chairman and ceo of Aptuit.

‘Focusing on our expertise in discovery and development services leverages our leadership position, and allows us to concentrate on delivering high-growth, high-value scientific services from discovery to mid-phase development.’